Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Investor Notice: Investigation Over Potential Wrongdoing

An investigation on behalf of investors in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) shares over potential wrongdoing at Lexicon Pharmaceuticals, Inc. was announced.

San Diego, CA — (SBWIRE) — 05/09/2022 — Certain directors of Lexicon Pharmaceuticals, Inc are under investigation over potential breaches of fiduciary duties.

Investors who purchased shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) and have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

The investigation by a law firm concerns whether certain Lexicon Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.

The Woodlands, TX based Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products.

On February 28, 2022, Lexicon Pharmaceuticals, Inc. announced the voluntary withdrawal of the Company’s New Drug Application for its glucose regulation drug, sotagliflozin, in order to correct a technical issue with the submission that had been recently identified by the Company.

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) declined from $3.29 per share on February 10, 2022. to as low as $1.77 per share on May 6, 2022.

Those who purchased shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Christopher Clausen
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit: http://www.sbwire.com/press-releases/lexicon-pharmaceuticals-inc-nasdaqlxrx-investor-notice-investigation-over-potential-wrongdoing-1357299.htm

Media Relations Contact

Christopher Clausen
Shareholders Foundation
Telephone: 1-858-779-1554
Email: Click to Email Christopher Clausen
Web: https://www.shareholdersfoundation.com/